“ Fast Track Designation accelerates ADP101's development path for the treatment of mono- and multi-food allergy “ “ Phase 1/2 Harmony data for ADP101 recently presented at the 2023 American College...
Results aligned with patient needs and clinical practice priorities Alladapt preparing for ADP101 Phase 3 study in 2024 MENLO PARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Alladapt...
Alladapt Immunotherapeutics said its food allergy drug helped children consume more of what they’re allergic to in a clinical trial, according to results presented on Sunday. Next, the Menlo Park, CA-based biotech is gearing up for a Phase III trial of its oral immunotherapy.
-Results from primary analysis conducted in pediatric patients demonstrate dose-dependent and clinically meaningful responses in addition to a favorable safety and tolerability profile- -Harmony,...
MENLO PARK, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
MENLO PARK, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
MENLO PARK, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address...
MENLO PARK, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, today announced that Ashley Dombkowski, Chief Executive Officer of Alladapt, will participate in a panel discussion entitled “Novel Immunology” at Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022 at 1:50 p.m. ET / 10:50 a.m. PT.
MENLO PARK, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, today announced that it has entered into a term loan agreement for up to $50 million with Hercules Capital, Inc. (NYSE: HTGC). The capital will be used to further support the clinical development of Alladapt’s lead asset ADP101 through initiation of a potential Phase 3 pivotal trial, as well as the completion of its manufacturing facility intended for late-stage clinical supply of ADP101 and potential commercial product.
Alladapt Immunotherapeutics has refilled the bank balance with $119 million in institutional financing from the likes of Novartis, which will be used to follow the biotech's dream of developing the first FDA-approved therapy to treat the majority of food allergy patients.